Oncology Research Program
The Institute's oncology program centers on cell therapy through its induced pluripotent stem cell (iPSC).
The Institute's research focuses on allogeneic (off-the shelf) iPSC program in which the iPSC are immune-tolerant and will not be rejected when administered to unrelated recipients. The Institute's cell therapy is based on its first-in-class virus-free and oncogene-free iPSC program coupled with its immune-tolerant adult stem cell platform. This research program will focus on the following treatments:
Universal bone marrow hematopoietic stem cells.
Universal CAR-T/NKC therapy for hematological cancers.
Universal CAR-T/NKC therapy for solid organ cancers.